2024 South

2024 Southern Hemisphere influenza vaccines cut hospitalisations in high-risk groups

Interim vaccine effectiveness (VE) estimates suggest that the 2024 Southern Hemisphere seasonal influenza vaccines were effective in preventing approximately one-third of influenza-related hospitalisations among high-risk groups, according to the US Centers for Disease Control and Prevention’s (CDC) latest Morbidity and Mortality Weekly Report. Employing data from a multicountry network, investigators estimated the interim VE against influenza-associated severe acute respiratory illness (SARI) hospitalisation using a test-negative case-control design. Interim estimates of influenza VE from ...

Babies Conceived After Fertility Treatment Have Higher Risk of Heart Defects

The risk of being born with a major heart defect is 36% higher in babies who were conceived after assisted reproductive technology, according to results of a very large study published in the European Heart Journal. Ulla-Britt Wennerholm, Universi...

Abdominal Body Fat Could Hint at CVD Risk, Even When Other Health Factors Are Not Considered

Having a high body roundness index (BRI) over a 6-year period was associated with an increased risk of developing cardiovascular disease (CVD) for adults aged older than 45 years, according to a study published in the Journal of the American Heart As...


Sixty Seconds Science


Spotify episodes

Apple podcasts

Google podcasts

Partner

Search:
Date
Filters:
Treatment
5:31

Treatment of cervical cancer in 2024 in the highlight of KEYNOTE-A18 study

Presenter: Remi Nout
Oncology
ESMO 2024
Adjuvant P
3:33

Adjuvant Pembrolizumab/Chemotherapy Misses DFS End Point in High-Risk Endometrial Cancer, but Benefits dMMR Subgroup

Presenter: Remi Nout
Oncology
ESMO 2024
Breast can
5:60

Breast cancer, early stage highlights of the ESMO 2024 Congress

Presenter: Ann H. Partridge
Oncology
ESMO 2024
Setting a
5:24

Setting a new benchmark for ALK+ aNSCLC targeted therapy - report from ESMO2024

Presenter: Tony S.K. Mok
Oncology
ESMO 2024
POD1UM-303
1:41

POD1UM-303/InterAACT 2: Potentially Practice-Changing Findings in SCAC - report from ESMO2024

Presenter: Dominik P. Modest
Oncology
ESMO 2024
Neoadjuvan
6:26

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study

Presenter: Peter Schmid
Oncology
ESMO 2024
PEACE-3 Tr
5:08

PEACE-3 Trial Shows Combination Therapy Improves Survival in Prostate Cancer

Presenter: Silke Gillessen
Oncology
ESMO 2024
Adding Met
4:05

Adding Metformin to ADT for Patients with mHSPC: Overall Survival Results from the Multi-Arm, Multi-Stage Randomized Platform Trial STAMPEDE

Presenter: Silke Gillessen
Oncology
ESMO 2024
New pillar
12:05

New pillars of optimal medical treatment in heart failure

Presenter: Michael Böhm
Cardiology
ESC 2024
Imroving L
6:14

Imroving Lung Health in the 21's century

Presenter: Joan B. Soriano
Respiratory
ERS 2024
Why is idi
10:26

Why is idiopathic pulmonary fibrosis not so idiopathic? - report from ERS2024

Presenter: Michael Kreuter
Respiratory
ERS 2024
Highlihts
18:36

Highlihts of ERS 2024 - The President's perspective

Presenter: Carlos Robalo Cordeiro
Respiratory
ERS 2024
Novel rese
3:23

Novel research data on asthma and chronic obstructive pulmonary disease management: clinical applications

Presenter: Charlotte Suppli Ulrik
Respiratory
ERS 2024
Thoracic o
9:49

Thoracic oncology - Lung cancer diagnostics and treatment challenges

Presenter: Maria Joana Pereira Catarata
Respiratory
ERS 2024
Overcoming
7:11

Overcoming the challenges of increasing urbanisation for respiratory health

Presenter: Ane Johannessen
Respiratory
ERS 2024
Pre-diabet
6:54

Pre-diabetes: a risk factor for cardiovascular disease? - report from ESC2024

Presenter: Antonio Ceriello
Cardiology
ESC 2024
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
The import
11:22

The importance of the anterior interface in eye surgery

Presenter: Marie-José Tassignon
Internal Medicine
Haematolog
17:26

Haematology is at the forefront - interview with EHA President

Presenter: Antonio Almeida
Oncology
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Oncology
General as
1:18

General aspects of the ESH2023 Hypertension Guidelines - What are the major changes?

Presenter: Michel Burnier
Cardiology
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
Cardiology
How to tre
1:06

How to treat patients optimally with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
Oncology
How novel
1:07

How novel AI model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia?

Presenter: Andrew Srisuwananukorn
Hematology
The future
1:10

The future of Multiple Myeloma management

Presenter: Xavier Leleu
Hematology
Benefits o
1:01

Benefits of myeloma regimens in the real world fall well short of trials

Presenter: Alissa Visram
Hematology
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
Cardiology
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
Cardiology
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Cardiology
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
Cardiology
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Cardiology
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Oncology